

NEUREN PHARMACEUTICALS LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING  
Tuesday, 28 May, 2024



As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	RE-ELECTION OF PATRICK DAVIES AS A DIRECTOR	NA	47,235,712 94.65%	2,544,453 5.10%	127,604 0.26%	36,302	51,338,336 95.28%	2,544,453 4.72%	36,302	Carried
2	AUDITOR FEES AND EXPENSES	NA	49,169,654 98.54%	598,915 1.20%	129,451 0.26%	46,051	53,274,125 98.89%	598,915 1.11%	46,051	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item